Elucidating Dynamics and Regulation of Alternative Splicing in Osteogenic Differentiation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
										Recommended publications
									
								- 
												  Atlas Antibodies in Breast Cancer Research Table of ContentsATLAS ANTIBODIES IN BREAST CANCER RESEARCH TABLE OF CONTENTS The Human Protein Atlas, Triple A Polyclonals and PrecisA Monoclonals (4-5) Clinical markers (6) Antibodies used in breast cancer research (7-13) Antibodies against MammaPrint and other gene expression test proteins (14-16) Antibodies identified in the Human Protein Atlas (17-14) Finding cancer biomarkers, as exemplified by RBM3, granulin and anillin (19-22) Co-Development program (23) Contact (24) Page 2 (24) Page 3 (24) The Human Protein Atlas: a map of the Human Proteome The Human Protein Atlas (HPA) is a The Human Protein Atlas consortium cell types. All the IHC images for Swedish-based program initiated in is mainly funded by the Knut and Alice the normal tissue have undergone 2003 with the aim to map all the human Wallenberg Foundation. pathology-based annotation of proteins in cells, tissues and organs expression levels. using integration of various omics The Human Protein Atlas consists of technologies, including antibody- six separate parts, each focusing on References based imaging, mass spectrometry- a particular aspect of the genome- 1. Sjöstedt E, et al. (2020) An atlas of the based proteomics, transcriptomics wide analysis of the human proteins: protein-coding genes in the human, pig, and and systems biology. mouse brain. Science 367(6482) 2. Thul PJ, et al. (2017) A subcellular map of • The Tissue Atlas shows the the human proteome. Science. 356(6340): All the data in the knowledge resource distribution of proteins across all eaal3321 is open access to allow scientists both major tissues and organs in the 3.
- 
												  Loss of Fam60a, a Sin3a Subunit, Results in Embryonic Lethality and Is Associated with Aberrant Methylation at a Subset of GeneRESEARCH ARTICLE Loss of Fam60a, a Sin3a subunit, results in embryonic lethality and is associated with aberrant methylation at a subset of gene promoters Ryo Nabeshima1,2, Osamu Nishimura3,4, Takako Maeda1, Natsumi Shimizu2, Takahiro Ide2, Kenta Yashiro1†, Yasuo Sakai1, Chikara Meno1, Mitsutaka Kadota3,4, Hidetaka Shiratori1†, Shigehiro Kuraku3,4*, Hiroshi Hamada1,2* 1Developmental Genetics Group, Graduate School of Frontier Biosciences, Osaka University, Suita, Japan; 2Laboratory for Organismal Patterning, RIKEN Center for Developmental Biology, Kobe, Japan; 3Phyloinformatics Unit, RIKEN Center for Life Science Technologies, Kobe, Japan; 4Laboratory for Phyloinformatics, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan Abstract We have examined the role of Fam60a, a gene highly expressed in embryonic stem cells, in mouse development. Fam60a interacts with components of the Sin3a-Hdac transcriptional corepressor complex, and most Fam60a–/– embryos manifest hypoplasia of visceral organs and die in utero. Fam60a is recruited to the promoter regions of a subset of genes, with the expression of these genes being either up- or down-regulated in Fam60a–/– embryos. The DNA methylation level of the Fam60a target gene Adhfe1 is maintained at embryonic day (E) 7.5 but markedly reduced at –/– *For correspondence: E9.5 in Fam60a embryos, suggesting that DNA demethylation is enhanced in the mutant. [email protected] (SK); Examination of genome-wide DNA methylation identified several differentially methylated regions, [email protected] (HH) which were preferentially hypomethylated, in Fam60a–/– embryos. Our data suggest that Fam60a is †These authors contributed required for proper embryogenesis, at least in part as a result of its regulation of DNA methylation equally to this work at specific gene promoters.
- 
												  Inherited Variation in Mir-290 Expression Suppresses Breast Cancer Progression by Targeting the Metastasis Susceptibility Gene Arid4bPublished OnlineFirst February 27, 2013; DOI: 10.1158/0008-5472.CAN-12-3513 Cancer Tumor and Stem Cell Biology Research Inherited Variation in miR-290 Expression Suppresses Breast Cancer Progression by Targeting the Metastasis Susceptibility Gene Arid4b Natalie Goldberger1, Renard C. Walker1, Chang Hee Kim2, Scott Winter1, and Kent W. Hunter1 Abstract The metastatic cascade is a complex and extremely inefficient process with many potential barriers. Understanding this process is of critical importance because the majority of cancer mortality is associated with metastatic disease. Recently, it has become increasingly clear that microRNAs (miRNA) play important roles in tumorigenesis and metastasis, yet few studies have examined how germline variations may dysregulate miRNAs, in turn affecting metastatic potential. To explore this possibility, the highly metastatic MMTV-PyMT mice were crossed with 25 AKXD (AKR/J Â DBA/2J) recombinant inbred strains to produce F1 progeny with varying metastatic indices. When mammary tumors from the F1 progeny were analyzed by miRNA microarray, miR-290 (containing miR-290-3p and miR-290-5p) was identified as a top candidate progression-associated miRNA. The microarray results were validated in vivo when miR-290 upregulation in two independent breast cancer cell lines suppressed both primary tumor and metastatic growth. Computational analysis identified breast cancer progression gene Arid4b as a top target of miR-290-3p, which was confirmed by luciferase reporter assay. Surprisingly, pathway analysis identified estrogen receptor (ER) signaling as the top canonical pathway affected by miR-290 upregulation. Further analysis showed that ER levels were elevated in miR-290–expressing tumors and positively correlated with apoptosis.
- 
												  Snapshot: the Splicing Regulatory Machinery Mathieu Gabut, Sidharth Chaudhry, and Benjamin J192 Cell SnapShot: The Splicing Regulatory Machinery Mathieu Gabut, Sidharth Chaudhry, and Benjamin J. Blencowe 133 Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5S 3E1, Canada Expression in mouse , April4, 2008©2008Elsevier Inc. Low High Name Other Names Protein Domains Binding Sites Target Genes/Mouse Phenotypes/Disease Associations Amy Ceb Hip Hyp OB Eye SC BM Bo Ht SM Epd Kd Liv Lu Pan Pla Pro Sto Spl Thy Thd Te Ut Ov E6.5 E8.5 E10.5 SRp20 Sfrs3, X16 RRM, RS GCUCCUCUUC SRp20, CT/CGRP; −/− early embryonic lethal E3.5 9G8 Sfrs7 RRM, RS, C2HC Znf (GAC)n Tau, GnRH, 9G8 ASF/SF2 Sfrs1 RRM, RS RGAAGAAC HipK3, CaMKIIδ, HIV RNAs; −/− embryonic lethal, cond. KO cardiomyopathy SC35 Sfrs2 RRM, RS UGCUGUU AChE; −/− embryonic lethal, cond. KO deficient T-cell maturation, cardiomyopathy; LS SRp30c Sfrs9 RRM, RS CUGGAUU Glucocorticoid receptor SRp38 Fusip1, Nssr RRM, RS ACAAAGACAA CREB, type II and type XI collagens SRp40 Sfrs5, HRS RRM, RS AGGAGAAGGGA HipK3, PKCβ-II, Fibronectin SRp55 Sfrs6 RRM, RS GGCAGCACCUG cTnT, CD44 DOI 10.1016/j.cell.2008.03.010 SRp75 Sfrs4 RRM, RS GAAGGA FN1, E1A, CD45; overexpression enhances chondrogenic differentiation Tra2α Tra2a RRM, RS GAAARGARR GnRH; overexpression promotes RA-induced neural differentiation SR and SR-Related Proteins Tra2β Sfrs10 RRM, RS (GAA)n HipK3, SMN, Tau SRm160 Srrm1 RS, PWI AUGAAGAGGA CD44 SWAP Sfrs8 RS, SWAP ND SWAP, CD45, Tau; possible asthma susceptibility gene hnRNP A1 Hnrnpa1 RRM, RGG UAGGGA/U HipK3, SMN2, c-H-ras; rheumatoid arthritis, systemic lupus
- 
												  Logistic Regression Analysis for the Identification of the Metastasis-Associated Signaling Pathways of OsteosarcomaINTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 41: 1233-1244, 2018 Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma YANG LIU1, WEI SUN2, XIAOJUN MA2, YUEDONG HAO3, GANG LIU3, XIAOHUI HU3, HOULAI SHANG3, PENGFEI WU3, ZEXUE ZHAO3 and WEIDONG LIU3 1Department of Orthopedics, Affiliated Hospital of Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia 028007; 2Department of Orthopaedics, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080; 3Department of Orthopedics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China Received February 20, 2017; Accepted September 26, 2017 DOI: 10.3892/ijmm.2018.3360 Abstract. Osteosarcoma (OS) is the most common histological migration were identified as the terms that were significantly type of primary bone cancer. The present study was designed different. ICAM1, PDGFB, PDGFRB and TGFB1 were iden- to identify the key genes and signaling pathways involved in the tified to be enriched in cell migration and regulation of cell metastasis of OS. Microarray data of GSE39055 were down- migration. Nucleotide excision repair and the Wnt signaling loaded from the Gene Expression Omnibus database, which pathway were the metastasis-associated pathways of OS. In included 19 OS biopsy specimens before metastasis (control addition, ICAM1, PDGFB, PDGFRB and TGFB1, which were group) and 18 OS biopsy specimens after metastasis (case involved in cell migration and regulation of cell migration may group). After the differentially expressed genes (DEGs) were affect the metastasis of OS. identified using the Linear Models for Microarray Analysis package, hierarchical clustering analysis and unsupervised Introduction clustering analysis were performed separately, using orange software and the self-organization map method.
- 
												  Analysis of Alternative Splicing Associated with Aging and Neurodegeneration in the Human BrainDownloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Research Analysis of alternative splicing associated with aging and neurodegeneration in the human brain James R. Tollervey,1 Zhen Wang,1 Tibor Hortoba´gyi,2 Joshua T. Witten,1 Kathi Zarnack,3 Melis Kayikci,1 Tyson A. Clark,4 Anthony C. Schweitzer,4 Gregor Rot,5 Tomazˇ Curk,5 Blazˇ Zupan,5 Boris Rogelj,2 Christopher E. Shaw,2 and Jernej Ule1,6 1MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, United Kingdom; 2MRC Centre for Neurodegeneration Research, King’s College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom; 3EMBL–European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom; 4Expression Research, Affymetrix, Inc., Santa Clara, California 95051, USA; 5Faculty of Computer and Information Science, University of Ljubljana, Trzˇasˇka 25, SI-1000 Ljubljana, Slovenia Age is the most important risk factor for neurodegeneration; however, the effects of aging and neurodegeneration on gene expression in the human brain have most often been studied separately. Here, we analyzed changes in transcript levels and alternative splicing in the temporal cortex of individuals of different ages who were cognitively normal, affected by frontotemporal lobar degeneration (FTLD), or affected by Alzheimer’s disease (AD). We identified age-related splicing changes in cognitively normal individuals and found that these were present also in 95% of individuals with FTLD or AD, independent of their age. These changes were consistent with increased polypyrimidine tract binding protein (PTB)– dependent splicing activity. We also identified disease-specific splicing changes that were present in individuals with FTLD or AD, but not in cognitively normal individuals.
- 
												  ARID4B Polyclonal AntibodyFor Research Use Only ARID4B Polyclonal antibody Catalog Number:24499-1-AP 3 Publications www.ptgcn.com Catalog Number: GenBank Accession Number: Recommended Dilutions: Basic Information 24499-1-AP BC130418 WB 1:500-1:1000 Size: GeneID (NCBI): IP 0.5-4.0 ug for IP and 1:500-1:2000 1000 μg/ml 51742 for WB IHC 1:20-1:200 Source: Full Name: IF 1:10-1:100 Rabbit AT rich interactive domain 4B (RBP1- Isotype: like) IgG Calculated MW: Purification Method: 1312 aa, 148 kDa Antigen affinity purification Observed MW: Immunogen Catalog Number: 100 kDa, 200 kDa AG21462 Applications Tested Applications: Positive Controls: IF, IHC, IP, WB,ELISA WB : MCF-7 cells; A549 cells, K-562 cells Cited Applications: IP : MCF-7 cells; WB IHC : human testis tissue; human breast cancer tissue Species Specificity: human IF : MCF-7 cells; Cited Species: human Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 ARID4B, also named as BRCAA1 or SAP180, is a 1312 amino acid protein, which contains one ARID domain. ARID4B Background Information localizes in the nucleus and cytoplasm. ARID4B as a transcription repressor may function in the assembly and/or enzymatic activity of the Sin3A corepressor complex or in mediating interactions between the complex and other regulatory complexes. ARID4B is highly expressed in the testis and in breast, lung, colon, pancreatic and ovarian cancers. Expressed at low levels in the thymus, prostate and ovary. Notable Publications Author Pubmed ID Journal Application Ti-Chun Chan 33052246 Theranostics WB Xiangxiang Liu 30305607 Cell Death Dis WB Wanjin Li 28805661 J Clin Invest WB Storage: Storage Store at -20ºC.
- 
												  Dynamic Changes in RNA–Protein Interactions and RNA Secondary Structure in Mammalian ErythropoiesisPublished Online: 27 July, 2021 | Supp Info: http://doi.org/10.26508/lsa.202000659 Downloaded from life-science-alliance.org on 30 September, 2021 Resource Dynamic changes in RNA–protein interactions and RNA secondary structure in mammalian erythropoiesis Mengge Shan1,2 , Xinjun Ji3, Kevin Janssen5 , Ian M Silverman3 , Jesse Humenik3, Ben A Garcia5, Stephen A Liebhaber3,4, Brian D Gregory1,2 Two features of eukaryotic RNA molecules that regulate their and RNA secondary structure. These techniques generally either post-transcriptional fates are RNA secondary structure and RNA- use chemical probing agents or structure-specific RNases (single- binding protein (RBP) interaction sites. However, a comprehen- stranded RNases (ssRNases) and double-stranded RNases [dsRNa- sive global overview of the dynamic nature of these sequence ses]) to provide site-specific evidence for a region being in single- or features during erythropoiesis has never been obtained. Here, we double-stranded configurations (4, 5). use our ribonuclease-mediated structure and RBP-binding site To date, the known repertoire of RBP–RNA interaction sites has mapping approach to reveal the global landscape of RNA sec- been built on a protein-by-protein basis, with studies identifying ondary structure and RBP–RNA interaction sites and the dynamics the targets of a single protein of interest, often through the use of of these features during this important developmental process. techniques such as crosslinking and immunoprecipitation se- We identify dynamic patterns of RNA secondary structure and RBP quencing (CLIP-seq) (6). In CLIP-seq, samples are irradiated with UV binding throughout the process and determine a set of corre- to induce the cross-linking of proteins to their RNA targets.
- 
												  Large-Scale Analysis of Genome and Transcriptome Alterations in Multiple Tumors Unveils Novel Cancer-Relevant Splicing NetworksDownloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks Endre Sebestyén1,*, Babita Singh1,*, Belén Miñana1,2, Amadís Pagès1, Francesca Mateo3, Miguel Angel Pujana3, Juan Valcárcel1,2,4, Eduardo Eyras1,4,5 1Universitat Pompeu Fabra, Dr. Aiguader 88, E08003 Barcelona, Spain 2Centre for Genomic Regulation, Dr. Aiguader 88, E08003 Barcelona, Spain 3Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), E08908 L’Hospitalet del Llobregat, Spain. 4Catalan Institution for Research and Advanced Studies, Passeig Lluís Companys 23, E08010 Barcelona, Spain *Equal contribution 5Correspondence to: [email protected] Keywords: alternative splicing, RNA binding proteins, splicing networks, cancer 1 Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting to be unveiled. We systematically analyzed mutation, copy number and gene expression patterns of 1348 RNA-binding protein (RBP) genes in 11 solid tumor types, together with alternative splicing changes in these tumors and the enrichment of binding motifs in the alternatively spliced sequences. Our comprehensive study reveals widespread alterations in the expression of RBP genes, as well as novel mutations and copy number variations in association with multiple alternative splicing changes in cancer drivers and oncogenic pathways. Remarkably, the altered splicing patterns in several tumor types recapitulate those of undifferentiated cells.
- 
												  Overview of Research on Fusion Genes in Prostate Cancer2011 Review Article Overview of research on fusion genes in prostate cancer Chunjiao Song1,2, Huan Chen3 1Medical Research Center, Shaoxing People’s Hospital, Shaoxing University School of Medicine, Shaoxing 312000, China; 2Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China; 3Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou 310000, China Contributions: (I) Conception and design: C Song; (II) Administrative support: Shaoxing Municipal Health and Family Planning Science and Technology Innovation Project (2017CX004) and Shaoxing Public Welfare Applied Research Project (2018C30058); (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Song; (V) Data analysis and interpretation: H Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chunjiao Song. No. 568 Zhongxing Bei Road, Shaoxing 312000, China. Email: [email protected]. Abstract: Fusion genes are known to drive and promote carcinogenesis and cancer progression. In recent years, the rapid development of biotechnologies has led to the discovery of a large number of fusion genes in prostate cancer specimens. To further investigate them, we summarized the fusion genes. We searched related articles in PubMed, CNKI (Chinese National Knowledge Infrastructure) and other databases, and the data of 92 literatures were summarized after preliminary screening. In this review, we summarized approximated 400 fusion genes since the first specific fusion TMPRSS2-ERG was discovered in prostate cancer in 2005. Some of these are prostate cancer specific, some are high-frequency in the prostate cancer of a certain ethnic group. This is a summary of scientific research in related fields and suggests that some fusion genes may become biomarkers or the targets for individualized therapies.
- 
												  Genome-Wide Analysis of the Alternative Splicing ProfilesJournal of Cancer 2020, Vol. 11 1542 Ivyspring International Publisher Journal of Cancer 2020; 11(6): 1542-1554. doi: 10.7150/jca.36998 Research Paper Genome-wide Analysis of the Alternative Splicing Profiles Revealed Novel Prognostic Index for Kidney Renal Cell Clear Cell Carcinoma Li Gao1#, Rong-quan He2#, Zhi-guang Huang1, Yi-wu Dang1, Yong-yao Gu1, Hai-biao Yan3, Sheng-hua Li3, Gang Chen1 1. Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China 2. Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China 3. Department of Urology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China # Li Gao and Rong-quan He contributed equally to this study. Corresponding authors: Sheng-hua Li: Tel: +86 0771-5356533; Fax: 0086-771-5350031; Email: [email protected]; Gang Chen: Tel: +86 0771-5356534; Fax: 0086-771-5356534; Email: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.05.25; Accepted: 2019.12.13; Published: 2020.01.14 Abstract Alternative splicing (AS) is a major mechanism that greatly enhanced the diversity of proteome. Mounting evidence demonstrated that aberration of AS are important steps for the initiation and progression of human cancers. Here, we comprehensively investigated the association between whole landscape of AS profiles and the survival outcome of renal cell carcinoma (RCC) patients using RNA-seq data from TCGA SpliceSeq.
- 
												  Dynamic Clonal Progression in Xenografts of Acute Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21Acute Lymphoblastic Leukemia SUPPLEMENTARY APPENDIX Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 Paul. B. Sinclair, 1 Helen H. Blair, 1 Sarra L. Ryan, 1 Lars Buechler, 1 Joanna Cheng, 1 Jake Clayton, 1 Rebecca Hanna, 1 Shaun Hollern, 1 Zoe Hawking, 1 Matthew Bashton, 1 Claire J. Schwab, 1 Lisa Jones, 1 Lisa J. Russell, 1 Helen Marr, 1 Peter Carey, 2 Christina Halsey, 3 Olaf Heidenreich, 1 Anthony V. Moorman 1 and Christine J. Harrison 1 1Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne; 2Depart - ment of Clinical Haematology, Royal Victoria Infirmary, Newcastle-upon-Tyne and 3Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, UK ©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2017.172304 Received: May 15, 2017. Accepted: February 8, 2018. Pre-published: February 15, 2018. Correspondence: [email protected] Supplementary methods Determination of xenograft experimental end points. Mice were checked daily for signs of ill health and routinely weighed once a week or more often if indicated. Mice were culled at end stage disease as defined by; weight gain of >20%, weight loss reaching 20% at any time or >10% maintained for 72 hours compared with weight at the start of the experiment, starey coat, porphyrin staining of eyes and nose or sunken eyes, persistent skin tenting, immobility, unresponsive or very aggressive behaviour, loss of upright stance, laboured respiration, blood staining or other discharge, signs of anaemia including extreme paleness of feet, tail and ears.